

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |                      |                        |           |
|---|----------------------|------------------------|-----------|
| <b>TRANSMITTAL FORM</b><br><br>(to be used for all correspondence after initial filing) | Application Number   | 09/915.814             |           |
|   | Filing Date          | 07/29/2001             |           |
|   | First Named Inventor | Madeline M. Butler     |           |
|   | Art Unit             | 1635                   |           |
|   | Examiner Name        | Jane Zara              |           |
| Total Number of Pages in This Submission  | 14                   | Attorney Docket Number | ISPH-0587 |

**RECEIVED**  
**CENTRAL FAX CENTER**  
**MAY 17 2005**

| ENCLOSURES (Check all that apply)   |   |   |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form                             | <input type="checkbox"/> Drawing(s)                                       | <input type="checkbox"/> After Allowance Communication to TC                            |
| <input type="checkbox"/> Fee Attached                                     | <input type="checkbox"/> Licensing-related Papers                         | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences     |
| <input checked="" type="checkbox"/> Amendment/Reply                       | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final                                      | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declaration(s)                        | <input type="checkbox"/> Power of Attorney, Revocation                    | <input type="checkbox"/> Status Letter  |
| <input checked="" type="checkbox"/> Extension of Time Request             | <input type="checkbox"/> Change of Correspondence Address                 | <input type="checkbox"/> Other Enclosure(s) (please identify below):                    |
| <input type="checkbox"/> Express Abandonment Request                      | <input type="checkbox"/> Terminal Disclaimer                              |   |
| <input type="checkbox"/> Information Disclosure Statement                 | <input type="checkbox"/> Request for Refund                               |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)           | <input type="checkbox"/> CD, Number of CD(s) _____                        |   |
| <input type="checkbox"/> Reply to Missing Parts/Incomplete Application    | <input type="checkbox"/> Landscape Table on CD                            |   |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | Remarks   |   |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT |   |          |        |
|--|---|----------|--------|
| Firm Name                                  | Isis Pharmaceuticals, Inc.  |          |        |
| Signature                                  |  |          |        |
| Printed name                               | Joeli L. Connolly   |          |        |
| Date                                       | 5/17/05   | Reg. No. | 54,044 |

| CERTIFICATE OF TRANSMISSION/MAILING   |   |      |           |
|---|---|------|-----------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: |   |      |           |
| Signature   |  |      |           |
| Typed or printed name   | Jamile Koupal   | Date | 5-17-2005 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN RE APPLICATION OF: BUTLER ET AL.  
SERIAL NO: 09/915,814  
Response to Office Action Dated: November 17, 2004  
PAGE 1 OF 11

DOCKET No: ISPH-0587

RECEIVED  
CENTRAL FAX CENTER

MAY 17 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Butler et al.**Confirmation No.: **6393**Application No.: **09/915,814**Group Art Unit: **1635**Filing Date: **July 26, 2001**Examiner: **Zara, Jane J.**For: **ANTISENSE MODULATION OF HORMONE-SENSITIVE LIPASE EXPRESSION**

I certify that this paper is being facsimile transmitted to the Patent and Trademark Office to facsimile number (703) 872-9306 on the date shown below.

Dated: 5-17-2005By: 

Janic Toupal

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT AND REQUEST FOR RECONSIDERATION**

In response to the Official Action dated November 17, 2004, reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

**Amendments to the Claims** are reflected in the listing of the claims that begins on page 2 of this paper.

**Remarks** begin on page 5 of this paper.